SeaStar Medical Holding Corporation (ICU)
SeaStar Medical Holding Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Denver, CO, US. The stock last traded at $3.39, down 8.13% on the session, giving a market capitalisation of $9.6M. On trailing twelve-month figures it carries a trailing P/E of -0.83, a net margin of -828.6%. Its beta of -1.04 implies it has historically moved less than the broad market.
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
SeaStar Medical Holding Corporation is most often compared with the following Healthcare names: